Fundraisings and IPOs

Date: 2020-10-15

Type of information: Fundraising

Company: Vectivbio (Switzerland)

Investors: Versant Ventures (USA) OrbiMed (USA) Novo Holdings (Denmark) BPI France (France) Tekla Healthcare Investors (USA) Inserm Transfer Initiative (France) Cowen Healthcare Investments (USA) Surveyor Capital (USA) Eventide Asset Management (USA)

Amount: $110 Million

Funding type: financing round

Planned used: Proceeds from the financing will be used to support the Phase III program of VectivBio’s lead investigational product, apraglutide, to treat short bowel syndrome (SBS), early commercialization activities and further development of the pipeline through business development initiatives. Phase II studies of apraglutide demonstrated the potential for once-weekly dosing.


  • On October 15, 2020, VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, has closed a $110 million crossover financing from new investors Surveyor Capital (a Citadel company), Cormorant Capital and Eventide Asset Management, with participation from existing investors Versant Ventures, OrbiMed, Novo Holdings, BPI France, Tekla Healthcare Investors, Inserm Transfer Initiative and Cowen Healthcare Investments.

Therapeutic area: Inflammatory diseases - Gastrointestinal diseases - Transplantation

Is general: Yes